Mirati Therapeutics discovered novel therapy, Adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) harbouring the KRASG12C Mutation.
Adagrasib is an investigational, selective and oral small-molecule inhibitor of KRASG12C which is developed to support target inhibition, as KRASG12C protein regenerates every 24-48 hours.
In several clinical trials, Adagrasib is currently being evaluated in combination with other anti-cancer therapies with strong scientific rationale for patients with advanced solid tumors.
Lung cancer is the most common type of cancer reaching 2.21 million new cases and 1.8 million deaths globally. Among lung cancers, nearly 85 percent cases result in non-small cell lung cancer (NSCLC) and about 15 percent cases result in small cell lung cancer (SCLC).
KRASG12C is the most common mutation found in non-small cell lung cancer (NSCLC), found among 14 percent of patients with lung adenocarcinoma.
